| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1035561820 |
| P356 | DOI | 10.1038/NRC2230 |
| P3181 | OpenCitations bibliographic resource ID | 60596 |
| P698 | PubMed publication ID | 17891190 |
| P50 | author | Elías Campo | Q5830202 |
| Dolors Colomer | Q43096016 | ||
| Pedro Jares | Q58035979 | ||
| P2860 | cites work | The Bcl-2 apoptotic switch in cancer development and therapy | Q24620437 |
| The DNA damage response: putting checkpoints in perspective | Q28131713 | ||
| Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation | Q28140810 | ||
| Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma | Q28263800 | ||
| Minireview: Cyclin D1: normal and abnormal functions | Q28279069 | ||
| Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug | Q28282479 | ||
| Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization | Q28290083 | ||
| HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics | Q28290352 | ||
| ATM and related protein kinases: safeguarding genome integrity | Q29547735 | ||
| Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age | Q29618409 | ||
| Functional interactions of the retinoblastoma protein with mammalian D-type cyclins | Q29618856 | ||
| The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus | Q29619815 | ||
| Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data | Q30951567 | ||
| In situ localization of follicular lymphoma: description and analysis by laser capture microdissection | Q31049018 | ||
| Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma | Q33259459 | ||
| Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes | Q33357506 | ||
| Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma | Q33364240 | ||
| Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma | Q33364244 | ||
| Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma | Q61312250 | ||
| Molecular diagnosis of t(11;14) in mantle cell lymphoma using two-colour interphase fluorescence in situ hybridization | Q71127548 | ||
| A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease | Q73062440 | ||
| t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia | Q73459806 | ||
| Spatial proximity of translocation-prone gene loci in human lymphomas | Q73531485 | ||
| Visualization of mono-allelic chromosomal aberrations 3′ and 5′ of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization | Q73903411 | ||
| Blastic mantle cell lymphoma associated with Burkitt‐type translocation and hypodiploidy | Q77231041 | ||
| Cyclin D1/PRAD1/BCL-1 alternative transcript [B] protein product in B-lymphoid malignancies with t(11;14)(q13;q32) translocation | Q77392061 | ||
| Mutations of Chk2 in primary hematopoietic neoplasms | Q77929239 | ||
| Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression | Q78634781 | ||
| Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes | Q80347650 | ||
| Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization | Q80894677 | ||
| Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias | Q81362541 | ||
| TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies | Q81631545 | ||
| Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins | Q83215997 | ||
| Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation | Q42801826 | ||
| ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances | Q43833429 | ||
| Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma | Q44086086 | ||
| Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network | Q44135718 | ||
| CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas | Q44189799 | ||
| Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy | Q44265652 | ||
| Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis | Q44484550 | ||
| Thalidomide therapy induces response in relapsed mantle cell lymphoma | Q44582819 | ||
| Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome | Q44730863 | ||
| Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms | Q45138887 | ||
| Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms | Q45247281 | ||
| The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status | Q46706369 | ||
| Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions | Q51597461 | ||
| Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. | Q52947124 | ||
| Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors | Q53356360 | ||
| The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. | Q53603846 | ||
| Mantle cell lymphoma-derived cell lines: unique research tools | Q53630718 | ||
| Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma | Q53651184 | ||
| Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma? | Q54633278 | ||
| Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. | Q54663102 | ||
| Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR. | Q54709200 | ||
| VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. | Q54765675 | ||
| ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. | Q55036524 | ||
| The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak | Q57279398 | ||
| Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309 | Q57279405 | ||
| Selective Inhibition of I B Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level | Q57279413 | ||
| Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability | Q57279418 | ||
| CDK4andMDM2Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-typeINK4a/ARFLocus | Q57279470 | ||
| Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis | Q57279567 | ||
| The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma | Q57279573 | ||
| A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus | Q61312211 | ||
| Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies | Q33369463 | ||
| Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma | Q33372761 | ||
| Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma | Q33706095 | ||
| Mechanisms of chromosomal translocations in B cell lymphomas | Q34405423 | ||
| Apoptosis-based therapies for hematologic malignancies | Q34556301 | ||
| Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma | Q34576803 | ||
| Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma | Q34983013 | ||
| Function of a human cyclin gene as an oncogene | Q34994859 | ||
| Linking cyclins to transcriptional control. | Q35012861 | ||
| Mantle cell lymphoma is characterized by inactivation of the ATM gene | Q35081325 | ||
| Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival | Q35828800 | ||
| Targeting death receptors in cancer with Apo2L/TRAIL. | Q35834889 | ||
| Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling | Q35848185 | ||
| Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma | Q35848973 | ||
| The CD5+ B-cell | Q35864122 | ||
| Mechanisms of B-cell lymphoma pathogenesis | Q36085626 | ||
| Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways | Q36254627 | ||
| Current treatment approaches for mantle-cell lymphoma | Q36254655 | ||
| Targeting histones and proteasomes: new strategies for the treatment of lymphoma | Q36254672 | ||
| Treatment of mantle cell lymphoma: current approach and future directions | Q36496414 | ||
| Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature | Q36629194 | ||
| The impact of translocations and gene fusions on cancer causation | Q36760027 | ||
| Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis | Q36807184 | ||
| ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma | Q38363906 | ||
| Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. | Q38433102 | ||
| Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization | Q38457830 | ||
| Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival | Q38584605 | ||
| Evaluation of novel cell cycle inhibitors in mantle cell lymphoma | Q40157194 | ||
| Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. | Q40164612 | ||
| Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma | Q40202733 | ||
| Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. | Q40280853 | ||
| Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines | Q40322845 | ||
| Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma | Q40330626 | ||
| Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas | Q40381482 | ||
| Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma | Q40397270 | ||
| In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. | Q40430809 | ||
| Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. | Q40468483 | ||
| Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. | Q40479135 | ||
| Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519. | Q40518890 | ||
| MCL-1 expression in B-cell non-Hodgkin's lymphomas | Q40519635 | ||
| Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. | Q40792693 | ||
| Alkaline Phosphatase-positive Malignant Lymphoma: A Subtype of B-cell Lymphomas | Q40825424 | ||
| Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias | Q41893936 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mantle cell lymphoma | Q268713 |
| pathogenesis | Q372016 | ||
| P304 | page(s) | 750-62 | |
| P577 | publication date | 2007-10-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics | |
| P478 | volume | 7 |
| Q52730895 | A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. |
| Q30907982 | A comparison between protein profiles of B cell subpopulations and mantle cell lymphoma cells |
| Q35134208 | A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma |
| Q38095502 | A daunting task: manipulating leukocyte function with RNAi |
| Q41362934 | A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress. |
| Q33399582 | A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma |
| Q33414307 | A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma |
| Q35793148 | A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma |
| Q38283586 | A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature |
| Q37059580 | ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors |
| Q89996308 | Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma |
| Q91819920 | Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study |
| Q38001798 | An overview of the mTOR pathway as a target in cancer therapy. |
| Q37727184 | Analysis of NF-kappaB signaling pathways by proteomic approaches |
| Q39467111 | Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model. |
| Q30498194 | Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma |
| Q38017791 | Autologous transplantation and management of younger patients with mantle cell lymphoma |
| Q39386127 | Bax345/BLyS: A novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin |
| Q33719167 | Biological and clinical significance of GSK-3beta in mantle cell lymphoma--an immunohistochemical study. |
| Q28730808 | Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma |
| Q34275054 | Borrelia infection and risk of non-Hodgkin lymphoma |
| Q34542087 | Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation |
| Q39107651 | Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis |
| Q37687430 | CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma |
| Q36628297 | CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma |
| Q46458333 | CD200 Expression in B-Cell Chronic Lymphoproliferative Disorders |
| Q38616175 | CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation |
| Q27612411 | CIViC database |
| Q35206717 | Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo |
| Q51072600 | Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. |
| Q51782637 | Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma |
| Q34255861 | Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma |
| Q38110232 | Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. |
| Q38369665 | Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. |
| Q37398843 | Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells |
| Q55459925 | Coexpression of cyclin D1 and alpha-internexin in oligodendroglial tumors. |
| Q84759924 | Colonic in situ mantle cell lymphoma |
| Q53099728 | Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index |
| Q35869498 | Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations |
| Q38965699 | Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma |
| Q34666165 | Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma |
| Q64256027 | Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma |
| Q39569796 | Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway |
| Q96304224 | Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer |
| Q38056761 | Current and emerging new treatment strategies for mantle cell lymphoma |
| Q41254748 | Current and emerging treatment options for mantle cell lymphoma |
| Q53172515 | Current therapeutic strategies for mantle cell lymphoma |
| Q28242623 | Cyclin D as a therapeutic target in cancer |
| Q39587826 | Cyclin D1 Inhibits Mitochondrial Activity in B Cells |
| Q52877460 | Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer |
| Q36170317 | Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia |
| Q39882401 | Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy |
| Q47615901 | Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines |
| Q41297044 | Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer |
| Q89498262 | Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms |
| Q54335649 | Cyclin D1, p16(INK) (4A) and p27(Kip1) in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis |
| Q46583765 | Cyclin D1-positive diffuse large B-cell lymphoma. |
| Q33895292 | Cyclin K and cyclin D1b are oncogenic in myeloma cells. |
| Q28251481 | DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1 |
| Q38730980 | Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. |
| Q34033355 | Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. |
| Q37406813 | Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. |
| Q36091283 | Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma |
| Q42928100 | Discovery and characterization of a novel CCND1/MRCK gene fusion in mantle cell lymphoma |
| Q39031250 | Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma |
| Q35809271 | Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry |
| Q54417112 | Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma. |
| Q36529929 | Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature |
| Q90087532 | Dysregulation of N6-methyladenosine regulators predicts poor patient survival in mantle cell lymphoma |
| Q45124918 | ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. |
| Q42325839 | Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice |
| Q55511985 | Early Generated B-1-Derived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphoma-like Neoplasia in Aged Mice. |
| Q50330020 | Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance |
| Q34000612 | Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo |
| Q39352014 | Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from diff erent tissue sites |
| Q35018535 | Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma. |
| Q38343572 | Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis |
| Q38103251 | Flipping the switch from g1 to s phase with e3 ubiquitin ligases |
| Q53097472 | Follicular dendritic cell tumour/sarcoma: a commonly misdiagnosed tumour in the thorax. |
| Q37738556 | Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents |
| Q24310804 | Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma |
| Q38345568 | Gene expression profiling in non-Hodgkin lymphomas |
| Q39190247 | Gene methylation and silencing of SOCS3 in mantle cell lymphoma |
| Q37629080 | Gene mutations and actionable genetic lesions in mantle cell lymphoma. |
| Q38819164 | Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets |
| Q47137919 | Genetic polymorphisms in cyclin D1 are associated with risk of renal cell cancer in the Chinese population |
| Q39141229 | Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. |
| Q37269010 | Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma |
| Q88654101 | Genomic landscape and prognostic analysis of mantle cell lymphoma |
| Q102063587 | Germline variants of DNA repair genes in early onset mantle cell lymphoma |
| Q27322637 | Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing |
| Q36237528 | HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells |
| Q37901574 | High chromosome number in hematological cancer cell lines is a negative predictor of response to the inhibition of Aurora B and C by GSK1070916. |
| Q33398788 | High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes |
| Q36561781 | High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival |
| Q47283403 | High-Throughput Block Optical DNA Sequence Identification |
| Q45775887 | High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival |
| Q91807451 | Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression |
| Q53276110 | How I treat: diagnosing and managing “in situ” lymphoma |
| Q38694168 | Ibrutinib for mantle cell lymphoma |
| Q36080584 | Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma |
| Q33908446 | Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma |
| Q31155991 | Identifying subset of genes that have influential impacts on cancer progression: a new approach to analyze cancer microarray data |
| Q84702932 | Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression |
| Q38071003 | In situ mantle cell lymphoma in the nasopharynx. |
| Q44114704 | Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. |
| Q45042803 | Increased tumor cell proliferation in mantle cell lymphoma is associated with elevated insulin-like growth factor 2 mRNA-binding protein 3 expression |
| Q35143462 | Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis |
| Q54543199 | Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks. |
| Q64063187 | Interest of FDG-PET in the Management of Mantle Cell Lymphoma |
| Q38353509 | Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism |
| Q39304903 | Investigation of effects and mechanisms of total flavonoids of Astragalus and calycosin on human erythroleukemia cells |
| Q39017105 | Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease |
| Q37626685 | Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma |
| Q39636243 | Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo |
| Q42188792 | Lentivirus-mediated knockdown of Krüppel-like factor 9 inhibits the growth of ovarian cancer |
| Q64957922 | Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma. |
| Q42142419 | Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma |
| Q45928054 | Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex. |
| Q39888339 | MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. |
| Q30452150 | Management of Mantle Cell Lymphoma: Key Challenges and Next Steps |
| Q39388451 | Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia |
| Q28075606 | Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents |
| Q88390120 | Mantle cell lymphoma presenting as bilateral adrenal huge masses |
| Q42080758 | Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. |
| Q84161330 | Mantle cell lymphoma stage IV affecting lacrimal glands, retro-orbital tissue, optic nerve and ocular motor muscles |
| Q38012084 | Mantle cell lymphoma: 2012 update on diagnosis, risk‐stratification, and clinical management |
| Q38165907 | Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management |
| Q38535489 | Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management |
| Q40126253 | Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management |
| Q84122250 | Mantle cell lymphoma: Frontline and salvage therapy |
| Q37579294 | Mantle cell lymphoma: are current therapies changing the course of disease? |
| Q34568868 | Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era |
| Q58010865 | Mantle cell lymphoma: transcriptional regulation by microRNAs |
| Q60046968 | Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies |
| Q38957493 | Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas. |
| Q34570975 | MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma |
| Q38075896 | MicroRNAs in mantle cell lymphoma |
| Q36296654 | Microarray analysis of embryo-derived bovine pluripotent cells: The vulnerable state of bovine embryonic stem cells |
| Q35127368 | Molecular Targeted Approaches in Mantle Cell Lymphoma |
| Q39247693 | Molecular characterization of chromosomal band 5p15.33: A recurrent breakpoint region in mantle cell lymphoma involving the TERT–CLPTM1L locus |
| Q36772172 | Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma |
| Q37401338 | Molecular outcome prediction in mantle cell lymphoma |
| Q36290246 | Molecular pathogenesis of mantle cell lymphoma |
| Q37149519 | Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features |
| Q39949741 | Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques |
| Q26821766 | New molecular targets in mantle cell lymphoma |
| Q26829315 | Nodal and leukemic small B-cell neoplasms |
| Q38132359 | Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance |
| Q39290199 | Novel agents in mantle cell lymphoma |
| Q38675161 | Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon? |
| Q39107517 | Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. |
| Q37470373 | Nuclear cyclin D1: an oncogenic driver in human cancer |
| Q84626091 | Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms |
| Q39695887 | PRDM1 is required for mantle cell lymphoma response to bortezomib |
| Q55610546 | Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy. |
| Q34245261 | Pathogenesis of human B cell lymphomas |
| Q34074921 | Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling |
| Q36329257 | Peripheral T-cell Lymphoma with Cyclin D1 overexpression: a case report. |
| Q58920117 | Polo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma |
| Q52729381 | Prognostic Value of Cyclin D1 and CD44 Expression in Gastric Adenocarcinoma. |
| Q43080849 | Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. |
| Q35989980 | Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside |
| Q34385029 | RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma |
| Q35750000 | RNAi Targeting CXCR4 Inhibits Tumor Growth Through Inducing Cell Cycle Arrest and Apoptosis |
| Q49659048 | Rac1 is a novel therapeutic target in mantle cell lymphoma |
| Q34410264 | Racial differences in mantle cell lymphoma in the United States |
| Q53178306 | Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. |
| Q34091061 | Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell Line |
| Q26858960 | Risk factors for etiology and prognosis of mantle cell lymphoma |
| Q34168461 | Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. |
| Q35618595 | SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide |
| Q37797484 | SOX11 expression in mantle cell lymphoma |
| Q37406791 | SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. |
| Q45330812 | SOX11 is a mantle cell lymphoma oncogene |
| Q45341298 | SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis |
| Q53141841 | SOXC and MiR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma. |
| Q41416975 | Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma |
| Q38104238 | Signaling through cyclin D-dependent kinases |
| Q99565942 | Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma |
| Q47111277 | Smoldering mantle cell lymphoma. |
| Q81752872 | Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2 |
| Q33959993 | Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells |
| Q44418379 | TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage |
| Q42558443 | Targeting Wnt pathway in mantle cell lymphoma-initiating cells. |
| Q37132788 | Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives |
| Q41241688 | Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma |
| Q57279328 | The Classification of Lymphoma: Updating the WHO Classification |
| Q37809817 | The IgH 3' regulatory region and its implication in lymphomagenesis. |
| Q39570078 | The alpha-fetoprotein (AFP) third domain: a search for AFP interaction sites of cell cycle proteins |
| Q38017789 | The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL) |
| Q55007581 | The molecular pathogenesis of mantle cell lymphoma. |
| Q42040698 | The potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesis |
| Q38891634 | The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line |
| Q49831534 | Therapeutic effects of β-elemene via attenuation of the Wnt/β-catenin signaling pathway in cervical cancer cells |
| Q84586504 | Therapy of Mantle Cell Lymphoma: New Treatment Options in an Old Disease or Vice Versa? |
| Q35146262 | Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma |
| Q42744045 | Tumour-promoting role of EMT-inducing transcription factor ZEB1 in mantle cell lymphoma |
| Q37143660 | Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. |
| Q37938600 | Unlocking the secrets of immunoglobulin receptors in mantle cell lymphoma: Implications for the origin and selection of the malignant cells |
| Q37772500 | Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. |
| Q38199196 | Use of mTOR inhibitors in the treatment of malignancies |
| Q85653321 | Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression |
| Q35572084 | WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells |
| Q88515440 | [Anti-tumor effects of 13-cis-retinoic acid combined with interferon α-2b in animal model of mantle cell lymphoma] |
| Q52716876 | miRNA‑222 promotes liver cancer cell proliferation, migration and invasion and inhibits apoptosis by targeting BBC3. |
| Q36952171 | microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics |
| Q53312593 | t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals |
Search more.